Rotigotine Versus Placebo to Evaluate the Efficacy on Depressive Symptoms in Idiopathic Parkinson's Disease Patients

Summary

The purpose of this study was to show superiority of Rotigotine over placebo on improvement of depressive symptoms in subjects with idiopathic Parkinson's disease.

Timeline

Start

2012-04

Primary completion

2014-10

Completion

2014-10

Outcome

Missed primary endpoint

registry p =0.1286; Difference in LS Mean -1.12 (95% CI -2.56 to 0.33) NCT01523301 ↗

paper No statistically significant improvement in depressive symptoms were observed with rotigotine versus placebo. PMID 27322571 ↗

Publications

• Chung SJ, Asgharnejad M, Bauer L, Ramirez F, Jeon B. Evaluation of rotigotine transdermal patch for the treatment of depressive symptoms in patients with Parkinson's disease. Expert Opin Pharmacother. 2016 Aug;17(11):1453-61. doi: 10.1080/14656566.2016.1202917. Epub 2016 Jul 7.

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	Rotigotine	Unknown	8 mg	Other
Subject	Rotigotine	Unknown	16 mg	Other

Indications